Syndax Pharmaceuticals, Inc.
SNDX
$20.11
-$0.31-1.49%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 49.71% | 27.77% | 27.83% | -5.56% | -17.19% |
| Total Depreciation and Amortization | -- | -- | 50.00% | -- | -- |
| Total Amortization of Deferred Charges | -50.00% | -103.33% | -- | -- | -- |
| Total Other Non-Cash Items | 61.70% | 7.50% | 47.14% | 65.63% | 31.57% |
| Change in Net Operating Assets | -9.32% | -143.25% | -285.09% | -165.54% | -5.81% |
| Cash from Operations | 47.10% | -21.08% | -13.18% | -22.54% | -13.90% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -59.22% | 130.35% | -16.45% | -32.17% | 194.71% |
| Cash from Investing | -59.22% | 130.33% | -16.60% | -32.17% | 194.71% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 751.40% | 56.82% | 102.65% | -18.49% | -57.10% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 751.40% | -98.30% | 102.65% | -18.49% | -57.10% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -4,385.56% | -14.51% | -70.42% | -391.99% | 99.95% |